Target subject :~Patients with Hemophilia A with FVIII inhibitors~Patients with severe Hemophilia A without FVIII inhibitors.
To evaluate Safety and efficacy and pharmacokinetics, FVIII Inhibitor titers of Hemlibra subcutaneous injection (SC inj.) in Korean Hemophilia A patients with/without FVIII Inhibitors.